FindTrial
Sign In

Evaluation of artificial liver system for the treatment of severe avian influenza A (H7N9): a prospective control study

Evaluation of artificial liver system for the treatment of severe avian influenza A (H7N9): a prospective control study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-14004238
Enrollment
Unknown
Registered
2014-01-22
Start date
2014-01-02
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

avian influenza A (H7N9)

Interventions

treatment group:Artificial liver system (combination of plasma exc
Control:Without artificial liver system

Sponsors

the First Affiliated Hospital, College of Medicine, Zhejiang University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged 16~65 years old; 2. Severe avian influenza A (H7N9); 3. Patient or his/her statutory agent is able to understand and sign informed consent.

Exclusion criteria

Exclusion criteria: 1. The history of immunologic suppression: such as tumor of hematological system or long-term use of prednisone, et al.; 2. contraindication of artificial liver system: such as severe allergy of plasma or active bleeding, et al.

Design outcomes

Primary

MeasureTime frame
mortality rate;cytokine;—

Secondary

MeasureTime frame
oxygenation index;APACHE ? score;hospital stay;—

Countries

China

Contacts

Public ContactLanjuan Li

State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, School of Medicine, Zhejiang University

ljli@zju.edu.cn+86 0571-87236458

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026